In the Kingdom of Saudi Arabia (KSA), hospital and population based statist
ics have shown that breast cancer has the highest crude frequency rate amon
g Saudi women. The scarcity of reports about the disease in the KSA has bee
n the impetus to this analysis about breast cancer in the eastern province
of KSA. Data on female patients with invasive breast carcinoma seen at King
Fahd Hospital of the University in the eastern province of KSA, were retro
spectively reviewed. The analysis intended to examine the pattern of the di
sease and the outcome for patients. Between 1985 and 1995, 292 patients wer
e identified. Their median age +/- SD (standard deviation) was 42 +/- 10.5
years. Most patients were younger than 50 years (78%) and were predominantl
y premenopausals (79%). Only 25 (9%) of patients had stage I cancer, whilst
130(44%) 90 (30%), and 47 (16%) had stage II, III, and IV, respectively. A
mong patients with known axillary nodal status (242 patients), only 37% wer
e node-negative whilst 32% and 31% had 1-3, and greater than or equal to 4
positive nodes, respectively. Adjuvant chemotherapy and tamoxifen were comm
only offered; nonetheless, other adjuvant modalities were rarely utilised.
The median follow-up +/- SD of all patients was 62.3 +/- 8.9 months: 152 pa
tients (52%) were alive with no evidence of disease, 25 (9%) were alive wit
h evidence of disease, and 115 (39%) were dead from breast cancer or its re
lated complications. The median survival of the entire group was not obtain
ed, but the 10-year projected survival was 55%. For stage I and II patients
, 118 (76%) were alive with a projected 10-year actuarial survival of 64%.
On the other hand, only 51 (57%) of patients with stage HI disease were ali
ve with a median survival of 41.5 months (95% Confidence interval (Cl), 18.
9 to 51.3). Patients with stage IV disease demonstrated a poor outcome with
a median survival of 23.5 (95%, Cl 12.2 to 31.4). Multivariate analyses we
re performed to explore the influence of independent variables on overall s
urvival (OS) for patients with non-metastatic disease. Besides the expected
adverse effect of disease progression, the favourable influence of adjuvan
t chemotherapy and tamoxifen prevailed. The amount of benefit gained from t
amoxifen, however, was small. Similar analyses were undertaken to determine
the influence of independent variables on progression-free survival (PFS).
These analyses ascertained the adverse effects of advanced stage and the f
avourable impact of adjuvant chemotherapy. Breast cancer in the KSA has fea
tures that are distinctive from those of industrialised countries. Survival
data, however, were comparable. The favourable influence of adjuvant chemo
therapy was evident on both OS and PFS. Adjuvant tamoxifen, however, had li
ttle effect. Due to its infrequent use, the role of other adjuvant modaliti
es could not be asserted.